ClinicalTrials.gg
CompletedNCT02220725Updated Feb 10, 2023Results posted

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

A Phase 3 interventional study of Andexanet and Placebo in Bleeding, sponsored by Portola Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by Portola Pharmaceuticals (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hemorrhage by AstraZeneca — none open to participants now, none under way, none of them phase 3. Hemorrhage · AstraZeneca.

Started
2014
with 1 other
Phase 3
4 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Hemorrhage by AstraZeneca, this one is one of 2 that started in 2014, is one of 4 in phase 3, and was the 5th registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

None of the 12 studies in Hemorrhage by AstraZeneca is open now. The open studies under Hemorrhage, anywhere →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Hemorrhage by AstraZeneca as a file.
02

Study summary

The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.

03

Conditions studied

  • Bleeding

Browse trials for

Keywords

  • Andexanet alpha
  • Anticoagulation
  • Antidote
  • Rivaroxaban
  • Anti-fXa inhibitor
  • PRT4445
  • Xarelto
  • Reversal agent
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reasonably healthy men and women aged 50 to 75

Exclusion criteria

Exclusion Criteria:

  • History of abnormal bleeding, active bleeding or risk factors for bleeding
  • History of thrombosis or risk factors for thrombosis
  • History of adult asthma or use of inhaled medications
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Andexanet 800mg bolus (Part I)

    Andexanet (antidote) - 800 mg bolus

    Biological: Andexanet · Other: Placebo

  • Experimental
    Andexanet 800mg + 960mg (Part II)

    800 mg bolus + 960 mg infusion (8 mg/min)

    Biological: Andexanet · Other: Placebo

Interventions

  • BiologicalAndexanet

    Also known as: Andexanet alpha, PRT4445

  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II)

    In Part 1, the primary endpoint was percent change from baseline in anti-fXa activity at the nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minutes or +5 minutes time point following the end of the bolus. In Part 2, the primary endpoint was the percent change from baseline in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion. The baseline for the primary endpoint in both parts was the anti-fXa activity just prior to administration of andexanet, 4 hours following the Day 4 dose of rivaroxaban. Anti-fXa activity was measured by a modified chromogenic assay.

    Time frame: Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)

Secondary outcomes

  1. Efficacy: Percent Change in Anti-fXa Activity (Part II)

    The percent change from baseline in anti-fXa activity at the nadir, following the bolus, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part II). Baseline was the last assessment obtained prior to the first dose of andexanet or placebo

    Time frame: Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part II)

  2. Efficacy: Number of Participants With ≥80% Reduction in the Anti-fXa Activity From Baseline to Nadir

    Number of participants with ≥80% reduction in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) {Part II\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo

    Time frame: Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)

  3. Efficacy: Change From Baseline in Free Rivaroxaban Concentration at the Nadir

    Change from baseline in free rivaroxaban concentration (ng/mL) at the nadir, when nadir was defined as the smaller value for free rivaroxaban at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Free plasma concentrations of rivaroxaban was determined using a validated method that involved analysis of citrated human plasma with high-throughput equilibrium dialysis followed by liquid chromatography mass spectrometry.

    Time frame: Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)

  4. Efficacy: Change in Thrombin Generation (ETP) From Baseline to Its Peak [Parts I and II]

    Change in ETP from baseline to its peak, where peak was defined as the largest value for ETP between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) {Part I\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo. ETP was measured using a tissue factor-initiated thrombin generation assay.

    Time frame: Baseline to +2 minutes or +10 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)

  5. Efficacy: Number of Participants With Thrombin Generation (ETP) Above the Lower Limit of the Derived Normal Range at Its Peak (mITT Population)

    Number of participants with ETP above the lower limit of the normal range at its peak, between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) \[Part I\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. ETP was measured using a tissue factor-initiated thrombin generation assay

    Time frame: Baseline to +2 minutes or +10 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)

07

Results

Posted Sep 25, 2018

Participant flow

Subject recruitment occurred at investigative site in the US between May 2014 through June 2015

Participant flow — Overall Study
MilestonePlacebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)
Started14271326
Completed14271324
Not completed0002
Withdrew: Lost to follow-up0001
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryEfficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II)

In Part 1, the primary endpoint was percent change from baseline in anti-fXa activity at the nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minutes or +5 minutes time point following the end of the bolus. In Part 2, the primary endpoint was the percent change from baseline in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion. The baseline for the primary endpoint in both parts was the anti-fXa activity just prior to administration of andexanet, 4 hours following the Day 4 dose of rivaroxaban. Anti-fXa activity was measured by a modified chromogenic assay.

Time frame:
Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Reported as:
Mean · Percent change in anti-fXa activity
Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II)
Percent change in anti-fXa activityPlacebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)
Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II)-18.39 ± 14.662-92.22 ± 10.697-44.75 ± 11.749-96.72 ± 1.838
Statistical analysis
  • Placebo (Part I) vs Andexanet (Part I) · 2-sided test exact Wilcoxon rank-sum tes · p = <0.0001 · Hodges-lehman estimate of shift: -70.14 · 95% CI -85.43 to -65.91
  • Placebo (Part II) vs Andexanet (Part II) · 2-sided test exact Wilcoxon rank-sum tes · p = <0.0001 · Hodges-lehman estimate of shift: -51.87 · 95% CI -57.95 to -47.03
SecondaryEfficacy: Percent Change in Anti-fXa Activity (Part II)

The percent change from baseline in anti-fXa activity at the nadir, following the bolus, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part II). Baseline was the last assessment obtained prior to the first dose of andexanet or placebo

Time frame:
Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part II)
Reported as:
Mean · Percent change in anti-fXa activity
Efficacy: Percent Change in Anti-fXa Activity (Part II)
Percent change in anti-fXa activityPlacebo (Part II)Andexanet (Part II)
Efficacy: Percent Change in Anti-fXa Activity (Part II)-23.62 ± 10.309-95.34 ± 1.611
Statistical analysis
  • Placebo (Part II) vs Andexanet (Part II) · 2-sided test exact Wilcoxon rank-sum tes · p = <0.0001 · Hodges-lehman estimate of shift: -74.45 · 95% CI -78.92 to -64.45
SecondaryEfficacy: Number of Participants With ≥80% Reduction in the Anti-fXa Activity From Baseline to Nadir

Number of participants with ≥80% reduction in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) {Part II\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo

Time frame:
Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Reported as:
Count of participants · Participants
Efficacy: Number of Participants With ≥80% Reduction in the Anti-fXa Activity From Baseline to Nadir
ParticipantsPlacebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)
Efficacy: Number of Participants With ≥80% Reduction in the Anti-fXa Activity From Baseline to Nadir026026
SecondaryEfficacy: Change From Baseline in Free Rivaroxaban Concentration at the Nadir

Change from baseline in free rivaroxaban concentration (ng/mL) at the nadir, when nadir was defined as the smaller value for free rivaroxaban at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Free plasma concentrations of rivaroxaban was determined using a validated method that involved analysis of citrated human plasma with high-throughput equilibrium dialysis followed by liquid chromatography mass spectrometry.

Time frame:
Baseline to +2 minutes or +5 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Reported as:
Mean · ng/mL
Efficacy: Change From Baseline in Free Rivaroxaban Concentration at the Nadir
ng/mLPlacebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)
Efficacy: Change From Baseline in Free Rivaroxaban Concentration at the Nadir-4.155 ± 2.8914-23.347 ± 6.2229-12.063 ± 5.2510-30.296 ± 8.1451
Statistical analysis
  • Placebo (Part II) vs Andexanet (Part II) · 2-sided test exact Wilcoxon rank-sum tes · p = <0.0001 · Hodges-lehmann estimate of shift: -18.00 · 95% CI -23.05 to -12.73
SecondaryEfficacy: Change in Thrombin Generation (ETP) From Baseline to Its Peak [Parts I and II]

Change in ETP from baseline to its peak, where peak was defined as the largest value for ETP between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) {Part I\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo. ETP was measured using a tissue factor-initiated thrombin generation assay.

Time frame:
Baseline to +2 minutes or +10 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Reported as:
Mean · nmol/min
Efficacy: Change in Thrombin Generation (ETP) From Baseline to Its Peak [Parts I and II]
nmol/minPlacebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)
Efficacy: Change in Thrombin Generation (ETP) From Baseline to Its Peak [Parts I and II]173.861 ± 104.25281314.193 ± 331.1670264.424 ± 140.67921510.368 ± 344.7691
Statistical analysis
  • Placebo (Part I) vs Andexanet (Part I) · 2-sided test exact Wilcoxon rank-sum tes · p = <0.0001 · Hodges-lehman estimate of shift: 1142.66 · 95% CI 1006.10 to 1281.40
  • Placebo (Part II) vs Andexanet (Part II) · 2-sided test exact Wilcoxon rank-sum tes · p = <0.0001 · Hodges-lehman estimate of shift: 1205.05 · 95% CI 1034.17 to 1400.79
SecondaryEfficacy: Number of Participants With Thrombin Generation (ETP) Above the Lower Limit of the Derived Normal Range at Its Peak (mITT Population)

Number of participants with ETP above the lower limit of the normal range at its peak, between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) \[Part I\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \[Part II\]. ETP was measured using a tissue factor-initiated thrombin generation assay

Time frame:
Baseline to +2 minutes or +10 minutes following the end of andexanet/placebo bolus (Part I), or 10 minutes prior to end of andexanet/placebo continuous infusion or 5 minutes after the end of andexanet/placebo continuous infusion (Part II)
Reported as:
Count of participants · Participants
Efficacy: Number of Participants With Thrombin Generation (ETP) Above the Lower Limit of the Derived Normal Range at Its Peak (mITT Population)
ParticipantsPlacebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)
Efficacy: Number of Participants With Thrombin Generation (ETP) Above the Lower Limit of the Derived Normal Range at Its Peak (mITT Population)126026

Adverse events

Collected over ~8 to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Part I)—0/14 (0%)0/14 (0%)
Andexanet (Part I)—0/27 (0%)5/27 (18.5%)
Placebo (Part II)—0/13 (0%)2/13 (15.4%)
Andexanet (Part II)—0/26 (0%)5/26 (19.2%)
Most frequent other events
Most frequent other events
EventPlacebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)
Infusion Related ReactionInjury, poisoning and procedural complications0/145/270/130/26
Muscle SpasmsMusculoskeletal and connective tissue disorders0/140/271/133/26
ConstipationGastrointestinal disorders0/140/271/132/26

Baseline characteristics

41 and 39 subjects were randomized in Part I and Part II of study, respectively

Age, Continuous
Age, Continuous(years)Placebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)Total
Mean54.4 ± 3.8455.6 ± 3.7958.1 ± 5.4557.0 ± 5.0856.2 ± 4.61
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Part I)Andexanet (Part I)Placebo (Part II)Andexanet (Part II)Total
Female6961132
Male81871548
08

Study locations

1 site
  • West Coast Clinical Trials
    Cypress, California 90630, United States
09

References and documents

Publications

  • Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11. PubMed 26559317 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 3 years 1 month after primary completion. A results delay was requested in Sep 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2014
First posted
Aug 20, 2014
Start
May 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results delay requested
Sep 19, 2017
Results first posted
Sep 25, 2018
Last update
Feb 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02220725
Responsible party
Sponsor
First posted
Aug 20, 2014
Start date
May 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Sep 25, 2018
Last update
Feb 10, 2023

Study contacts

Vandana Mathur, M.D.
study director · Portola Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PRT064445

Start the discussion